Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABL1 | P00519 | 4/20 | 0.36 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.35 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.35 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.34 |
| ▸ | HCAR3 | P49019 | 1/20 | 0.34 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.33 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.33 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.33 |
| ▸ | CDK1 | P06493 | 1/20 | 0.31 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.31 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.31 |
| ▸ | CDK2 | P24941 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30442219 | 1.00 | ABL1 (0.36) | ABL1ADORA2AADORA1MAPK14HCAR3 | |
| SCHEMBL21989539 | 0.85 | ADORA2A (0.35) | ADORA2AADORA1 | |
| SCHEMBL30674854 | 0.85 | ADORA2A (0.35) | ADORA2AADORA1 | |
| SCHEMBL21989541 | 0.85 | ADORA2A (0.35) | ADORA2AADORA1 | |
| SCHEMBL21989321 | 0.81 | ABL1 (0.35) | ABL1ADORA2AADORA1HCAR3CDK1 | |
| SCHEMBL30674813 | 0.81 | ADORA2A (0.45) | ABL1ADORA2AADORA1MAPK14HCAR3 | |
| SCHEMBL21989637 | 0.81 | ADORA2A (0.45) | ABL1ADORA2AADORA1MAPK14HCAR3 | |
| SCHEMBL30441479 | 0.81 | ABL1 (0.35) | ABL1ADORA2AADORA1HCAR3CDK1 | |
| SCHEMBL25191287 | 0.77 | ABL1 (0.36) | ABL1ADORA2AADORA1HCAR3 | |
| SCHEMBL25200403 | 0.77 | LMNA (0.36) | ABL1ADORA2AADORA1HCAR3CDK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4371987-B9 | SUBSTITUTED 6-AZABENZIMIDAZOLE COMPOUNDS AS HPK1 INHIBITORS | GILEAD SCIENCES INC (US) | 2025-11-26 | — | — | EP | disclosed |
| EP-4371987-B1 | SUBSTITUTED 6-AZABENZIMIDAZOLE COMPOUNDS AS HPK1 INHIBITORS | GILEAD SCIENCES INC (US) | 2025-09-17 | — | — | EP | disclosed |
| US-12258346-B2 | Substituted 6-azabenzimidazole compounds | GILEAD SCIENCES, INC. (US) | 2025-03-25 | — | — | US | disclosed |
| US-20240400587-A1 | BIFUNCTIONAL DEGRADERS OF HEMATOPOIETIC PROGENITOR KINASE AND THERAPEUTIC USES THEREOF | NURIX THERAPEUTICS INC (US) | 2024-12-05 | — | — | US | disclosed |
| EP-4430052-A1 | BIFUNCTIONAL DEGRADERS OF HEMATOPOIETIC PROGENITOR KINASE AND THERAPEUTIC USES THEREOF | Nurix Therapeutics, Inc. (US) | 2024-09-18 | — | — | EP | disclosed |
| US-12091426-B2 | Bifunctional degraders of hematopoietic progenitor kinase and therapeutic uses thereof | NURIX THERAPEUTICS, INC. (US) | 2024-09-17 | — | — | US | disclosed |
| US-20240287061-A1 | SUBSTITUTED 6-AZABENZIMIDAZOLE COMPOUNDS | GILEAD SCIENCES, INC. | 2024-08-29 | — | — | US | disclosed |
| CN-113227089-B | Substituted 6-azabenzimidazole compounds as HPK1 inhibitors | 吉利德科学公司 | 2024-07-05 | — | — | CN | disclosed |
| EP-4371987-A1 | SUBSTITUTED 6-AZABENZIMIDAZOLE COMPOUNDS AS HPK1 INHIBITORS | Gilead Sciences, Inc. (US) | 2024-05-22 | — | — | EP | disclosed |
| US-11925631-B2 | Substituted 6-azabenzimidazole compounds | GILEAD SCIENCES, INC. (US) | 2024-03-12 | — | — | US | disclosed |
| EP-3873903-A1 | SUBSTITUTED 6-AZABENZIMIDAZOLE COMPOUNDS AS HPK1 INHIBITORS | GILEAD SCIENCES, INC. (US) | 2021-09-08 | — | — | EP | disclosed |
| EP-3873608-A1 | SUBSTITUTED 6-AZABENZIMIDAZOLE COMPOUNDS HAVING HPK1 INHIBITORY ACTIVITY | GILEAD SCIENCES, INC. (US) | 2021-09-08 | — | — | EP | disclosed |
| CN-113227089-A | Substituted 6-azabenzimidazole compounds as HPK1 inhibitors | 吉利德科学公司 | 2021-08-06 | — | — | CN | disclosed |
| US-11071730-B2 | Substituted 6-azabenzimidazole compounds | GILEAD SCIENCES, INC. (US) | 2021-07-27 | — | — | US | disclosed |
| US-11071730-B2 | Substituted 6-azabenzimidazole compounds | GILEAD SCIENCES, INC. (US) | 2021-07-27 | — | — | US | disclosed |
| CN-112969505-A | Substituted 6-azabenzimidazole compounds having HPK1 inhibiting activity | 吉利德科学公司 | 2021-06-15 | — | — | CN | disclosed |
| US-20210115037-A1 | SUBSTITUTED 6-AZABENZIMIDAZOLE COMPOUNDS | GILEAD SCIENCES, INC. | 2021-04-22 | — | — | US | disclosed |
| US-20210115037-A1 | SUBSTITUTED 6-AZABENZIMIDAZOLE COMPOUNDS | GILEAD SCIENCES, INC. | 2021-04-22 | — | — | US | disclosed |
| US-20200171020-A1 | SUBSTITUTED 6-AZABENZIMIDAZOLE COMPOUNDS | GILEAD SCIENCES, INC. | 2020-06-04 | — | — | US | disclosed |
| US-20200171020-A1 | SUBSTITUTED 6-AZABENZIMIDAZOLE COMPOUNDS | GILEAD SCIENCES, INC. | 2020-06-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240287061-A1 | SUBSTITUTED 6-AZABENZIMIDAZOLE COMPOUNDS | CDK6, HIPK1, DCK | ABL1 172/4885ADORA2A 2255/4885ADORA1 3041/4885 |
| US-12258346-B2 | Substituted 6-azabenzimidazole compounds | CDK6, HIPK1, DCK | ABL1 172/4885ADORA2A 2255/4885ADORA1 3041/4885 |
| US-11925631-B2 | Substituted 6-azabenzimidazole compounds | CDK6, HIPK1, DCK | ABL1 172/4885ADORA2A 2255/4885ADORA1 3041/4885 |
| US-20210115037-A1 | SUBSTITUTED 6-AZABENZIMIDAZOLE COMPOUNDS | CDK6, HIPK1, DCK | ABL1 172/4885ADORA2A 2255/4885ADORA1 3041/4885 |
| US-11071730-B2 | Substituted 6-azabenzimidazole compounds | CDK6, HIPK1, DCK | ABL1 172/4885ADORA2A 2255/4885ADORA1 3041/4885 |
| US-20200171020-A1 | SUBSTITUTED 6-AZABENZIMIDAZOLE COMPOUNDS | CDK6, HIPK1, DCK | ABL1 172/4885ADORA2A 2255/4885ADORA1 3041/4885 |
| US-12091426-B2 | Bifunctional degraders of hematopoietic progenitor kinase and therapeutic uses thereof | TTK, HIPK1, CLK1 | ABL1 386/4885ADORA2A 4195/4885ADORA1 4606/4885 |
| US-20240400587-A1 | BIFUNCTIONAL DEGRADERS OF HEMATOPOIETIC PROGENITOR KINASE AND THERAPEUTIC USES THEREOF | TTK, HIPK1, CLK1 | ABL1 386/4885ADORA2A 4195/4885ADORA1 4606/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.